Non Alcoholic Fatty Liver Disease (NAFLD) Market

DelveInsight’s “Non-alcoholic Fatty Liver Disease (NAFLD) – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Non-alcoholic Fatty Liver Disease, historical and forecasted epidemiology as well as the Non-alcoholic Fatty Liver Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Non-alcoholic Fatty Liver Disease market report provides current treatment practices, emerging drugs, Non-alcoholic Fatty Liver Disease market share of individual therapies, and current and forecasted Non-alcoholic Fatty Liver Disease market size from 2019 to 2032, segmented by seven major markets. The report also covers current Non-alcoholic Fatty Liver Disease treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study period: 2019–2032

Non-alcoholic Fatty Liver Disease Understanding and Treatment Algorithm

The DelveInsight’s Non-alcoholic Fatty Liver Disease market report gives a thorough understanding of Non-alcoholic Fatty Liver Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Non-alcoholic Fatty Liver Disease is a very common disorder and refers to a group of conditions where there is an accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of Non-alcoholic Fatty Liver Disease is a non-serious condition called fatty liver. In fatty liver, fat accumulates in the liver cells. Although having fat in the liver is not normal, by itself it probably does not damage the liver. A small group of people with Non-alcoholic Fatty Liver Disease may have a more serious condition named non-alcoholic steatohepatitis (NASH). In non-alcoholic steatohepatitis, fat accumulation is associated with liver cell inflammation and different degrees of scarring.

The majority of individuals with Non-alcoholic Fatty Liver Disease have no symptoms and a normal examination. Children may exhibit symptoms such as abdominal pain, which may be in the center or the right upper part of the abdomen, and sometimes fatigue. However, other causes of abdominal pain and fatigue should be considered. On physical examination, the liver might be slightly enlarged and some children may have patchy, dark discoloration of the skin present (acanthosis nigricans) most commonly over the neck and the underarm area. Non-alcoholic Fatty Liver Disease is part of the metabolic syndrome characterized by diabetes, or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. Not all patients have all the manifestations of metabolic syndrome. Less is known about what causes Non-alcoholic Fatty Liver Disease to develop. Researchers are focusing on several factors that may contribute to the development of Non-alcoholic Fatty Liver Disease. These include oxidative stress (imbalance between pro-oxidant and anti-oxidant chemicals that lead to liver cell damage); production and release of toxic inflammatory proteins (cytokines) by the patient’s own inflammatory cells, liver cells, or fat cells; liver cell necrosis or death, called apoptosis; adipose tissue (fat tissue) inflammation and infiltration by white blood cells; and gut microbiota (intestinal bacteria) which may play a role in liver inflammation. Obesity is thought to be the most common cause of fatty infiltration of the liver. Some experts estimate that about two-thirds of obese adults and half of the obese children may have fatty liver. The number of children who have non-alcoholic steatohepatitis is not known. The presence of type 2 diabetes and other conditions associated with insulin resistance, such as polycystic ovarian syndrome are known risk factors for the development of fatty liver and non-alcoholic steatohepatitis.

Non-alcoholic Fatty Liver Disease diagnosis

After physical examination, the next step remains to determine whether the patient with fatty liver has only fat within their liver (also called steatosis), where scarring of the liver is rare or non-alcoholic steatohepatitis with both fat and inflammation in the liver that over time can cause scarring in the liver. The most accurate way to figure this out is to perform a liver biopsy. There are a growing number of alternatives to liver biopsy that can also provide much of the same information without requiring needle insertion into the liver. These include measuring liver stiffness and fat content of the liver with elastography testing through the use of a specialized ultrasound (Fibroscan) or MRI scan. Special blood tests or a combination of routine blood tests can also be used to evaluate for possible liver scarring in patients with Non-alcoholic Fatty Liver Disease. Because none of these tests are perfect, patients with fatty liver are advised to discuss the risks and benefits of these tests with their doctor to decide which tests are best for their situation. In general, it is most beneficial to do a combination of tests to see if they all point to the same degree of fat in the liver and liver scarring.

Non-alcoholic Fatty Liver Disease treatment

Currently, there are no FDA-approved medications specifically for the treatment of Non-alcoholic Fatty Liver Disease, but various medicines can be useful in managing the problems associated with the condition. However, studies have shown that both fat, inflammation and scar tissue can leave the liver. This means that Non-alcoholic Fatty Liver Disease and non-alcoholic steatohepatitis can be reversible. Improving liver fat and inflammation is possible when people lose weight and/or modify their lifestyle. This is the first-line treatment for Non-alcoholic Fatty Liver Disease and non-alcoholic steatohepatitis. Patients with non-alcoholic steatohepatitis diagnosed with a liver biopsy and who do not have diabetes, significant heart disease, or cirrhosis will sometimes be asked to start Vitamin E as this is thought to help reduce liver inflammation. Various medicines can be useful in managing the problems associated with the condition, for example, the doctor may recommend medicine to treat high blood pressure, high cholesterol, type 2 diabetes, and obesity. If one develops severe cirrhosis, it may require a liver transplant or it may be possible to have a transplant using a section of the liver removed from a living donor. As the liver can regenerate itself, both the transplanted section and the remaining section of the donor's liver are able to regrow to normal size.

Non-alcoholic Fatty Liver Disease Epidemiology

The Non-alcoholic Fatty Liver Disease epidemiology section provides insights into the historical and current Non-alcoholic Fatty Liver Disease patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Non-alcoholic Fatty Liver Disease report also provides the diagnosed patient pool, their trends, and assumptions undertaken.

Key findings

According to American Liver Foundation (2022), Non-alcoholic Fatty Liver Disease is the most common chronic liver condition in the United States. It’s estimated that about 25% of adults in the US have Non-alcoholic Fatty Liver Disease. Of those with Non-alcoholic Fatty Liver Disease, about 20% have non-alcoholic steatohepatitis (5% of adults in the US). Most people with Non-alcoholic Fatty Liver Disease have simply fatty liver.

According to the study conducted by Foschi et al. (2019), titled, “Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study,” the prevalence of Non-alcoholic Fatty Liver Disease was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes.

The Non-alcoholic Fatty Liver Disease epidemiology covered in the report provides historical as well as forecasted Non-alcoholic Fatty Liver Disease epidemiology [segmented as Total Prevalent Cases of Non-alcoholic Fatty Liver Disease, Diagnosed Cases of Non-alcoholic Fatty Liver Disease, Gender-specific Cases of Non-alcoholic Fatty Liver Disease, Age-specific Cases of Non-alcoholic Fatty Liver Disease, Stage-specific Cases of Non-alcoholic Fatty Liver Disease, and Treatable Cases of Non-alcoholic Fatty Liver Disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Non-alcoholic Fatty Liver Disease Epidemiology

The epidemiology segment also provides the Non-alcoholic Fatty Liver Disease epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Non-alcoholic Fatty Liver Disease Drug Chapters

The drug chapter segment of the Non-alcoholic Fatty Liver Disease report encloses a detailed analysis of Non-alcoholic Fatty Liver Disease marketed drugs and late-stage (Phase III and Phase II) Non-alcoholic Fatty Liver Disease pipeline drugs. It also helps understand the Non-alcoholic Fatty Liver Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Non-alcoholic Fatty Liver Disease drugs

The report details the emerging Non-alcoholic Fatty Liver Disease therapies under the late and mid-stage of development for Non-alcoholic Fatty Liver Disease treatment.

Non-alcoholic Fatty Liver Disease Market Outlook

The Non-alcoholic Fatty Liver Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-alcoholic Fatty Liver Disease market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Non-alcoholic Fatty Liver Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Non-alcoholic Fatty Liver Disease market in the 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Non-alcoholic Fatty Liver Disease market in the 7MM.

The United States: Non-alcoholic Fatty Liver Disease Market Outlook

This section provides the total Non-alcoholic Fatty Liver Disease market size and market size by therapies in the United States.

EU4 and the UK Countries: Non-alcoholic Fatty Liver Disease Market Outlook

The total Non-alcoholic Fatty Liver Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Non-alcoholic Fatty Liver Disease Market Outlook

The total Non-alcoholic Fatty Liver Disease market size and market size by therapies in Japan are also mentioned.

Non-alcoholic Fatty Liver Disease Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Non-alcoholic Fatty Liver Disease market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Non-alcoholic Fatty Liver Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

This will help in understanding the Non-alcoholic Fatty Liver Disease drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Non-alcoholic Fatty Liver Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Non-alcoholic Fatty Liver Disease’s key players involved in developing targeted therapeutics.

Non-alcoholic Fatty Liver Disease market clinical trial development activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Non-alcoholic Fatty Liver Disease's emerging therapies.

Non-alcoholic Fatty Liver Disease Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Non-alcoholic Fatty Liver Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Non-alcoholic Fatty Liver Disease market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Non-alcoholic Fatty Liver Disease market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• Descriptive overview of Non-alcoholic Fatty Liver Disease, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Non-alcoholic Fatty Liver Disease epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Non-alcoholic Fatty Liver Disease, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Non-alcoholic Fatty Liver Disease market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based market forecasting determines the trends shaping and driving the global Non-alcoholic Fatty Liver Disease market

Report Highlights

• In the coming years, the Non-alcoholic Fatty Liver Disease market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Non-alcoholic Fatty Liver Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing Non-alcoholic Fatty Liver Disease therapies. The launch of emerging therapies will significantly impact the Non-alcoholic Fatty Liver Disease market
• A better understanding of Non-alcoholic Fatty Liver Disease pathogenesis will also contribute to the development of novel therapeutics for Non-alcoholic Fatty Liver Disease
• Our in-depth analysis of the Non-alcoholic Fatty Liver Disease pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Non-alcoholic Fatty Liver Disease Report Insights

• Patient-Based Market Forecasting
• Therapeutic approaches
• Non-alcoholic Fatty Liver Disease pipeline analysis
• Non-alcoholic Fatty Liver Disease market size and trends
• Non-alcoholic Fatty Liver Disease market opportunities
• Impact of upcoming therapies

Non-alcoholic Fatty Liver Disease Report Key Strengths

• 11 years forecast
• 7MM Coverage
• Non-alcoholic Fatty Liver Disease epidemiology segmentation
• Key cross competition
• KOL views
• Non-alcoholic Fatty Liver Disease drugs uptake

Non-alcoholic Fatty Liver Disease Report Assessment

• Current treatment practices
• Unmet needs
• Non-alcoholic Fatty Liver Disease pipeline product profiles
• Non-alcoholic Fatty Liver Disease market attractiveness

Key Questions

Non-alcoholic Fatty Liver Disease market insights:

• What would be the Non-alcoholic Fatty Liver Disease market growth till 2032, and what will be the resultant market size in 2032?
• What was the Non-alcoholic Fatty Liver Disease drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Non-alcoholic Fatty Liver Disease total market size and market size by therapies across the 7MM during the forecast period (2022–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Non-alcoholic Fatty Liver Disease market size during the forecast period (2022–2032)?
• How would the unmet needs affect the Non-alcoholic Fatty Liver Disease market dynamics and subsequent analysis of the associated trends?

Non-alcoholic Fatty Liver Disease Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Non-alcoholic Fatty Liver Disease?
• What is the historical and forecasted Non-alcoholic Fatty Liver Disease patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Non-alcoholic Fatty Liver Disease in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Non-alcoholic Fatty Liver Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-alcoholic Fatty Liver Disease and its status, along with the challenges faced?

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Non-alcoholic Fatty Liver Disease market
• Organize sales and marketing efforts by identifying the best opportunities for Non-alcoholic Fatty Liver Disease in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors